The human immunodeficiency virus specifically targets cells bearing CD4 receptors, primarily helper T-lymphocytes. As the virus replicates inside these cells, it destroys them, causing a gradual decline in cell-mediated immunity. A healthy adult typically maintains a CD4 count between 500 and 1500 cells per cubic millimeter. When this count drops below 200 cells per cubic millimeter, the body loses its capacity to defend against pathogens that a normal immune system easily repels. This severe immune breakdown defines acquired immunodeficiency syndrome and sets the stage for multiple secondary illnesses.
When immune surveillance fails, pathogens that rarely trouble healthy individuals take advantage of the compromised host. These opportunistic infections affect nearly every organ system in the body.
Persistent immune suppression and chronic viral coinfections create an environment where abnormal cell growth goes unchecked. Two prominent malignancies define the clinical landscape of advanced disease.
The virus readily crosses the blood-brain barrier early in infection, infecting microglia and macrophages within the central nervous system. This direct viral presence and chronic neuroinflammation lead to a spectrum of neurological disorders. HIV-associated neurocognitive disorder manifests as memory loss, difficulty concentrating, and slowed thinking processes. Patients may also experience peripheral neuropathy, characterized by burning pain, numbness, and tingling in the lower extremities, which is often exacerbated by certain older antiretroviral agents or the disease process itself.
Long-term management of chronic viral infection involves sustained inflammation and lifelong medication use, both of which contribute to metabolic alterations. Patients frequently develop dyslipidemia, insulin resistance, and lipodystrophy, which involves abnormal fat redistribution with central adiposity and peripheral wasting. These metabolic shifts, combined with chronic immune activation, significantly elevate the risk of cardiovascular disease, myocardial infarction, and stroke compared to the general population.
Living with a chronic, stigmatized condition profoundly impacts emotional well-being. Depression and anxiety disorders occur at significantly higher rates among affected individuals due to the psychological burden of diagnosis, fear of disclosure, social stigma, and physical symptom distress. Economic strain and lifestyle adjustments further compound these challenges. Mental health struggles not only reduce quality of life but can also interfere with consistent medication adherence, creating a dangerous cycle of clinical deterioration.
Rigorous clinical assessment is necessary to catch evolving complications early. Nurses must monitor laboratory trends closely, tracking CD4 counts to gauge immune status and viral load to measure treatment effectiveness. Routine screening should include assessing for signs of new infections, evaluating cognitive changes using simple screening tools, checking peripheral sensation in the feet, and monitoring metabolic parameters such as blood glucose and lipid profiles. Regular physical inspections for skin lesions like Kaposi sarcoma or oral thrush are also essential during every clinical visit.
Effective care requires a multidisciplinary approach focused on sustaining viral suppression and supporting overall health. Nurses play a frontline role in educating patients on the strict importance of taking antiretroviral therapy exactly as prescribed to prevent drug resistance. Education must also cover recognizing early signs of opportunistic infections, adopting heart-healthy nutrition to combat metabolic risks, and practicing safe sex to prevent reinfection or transmission. Establishing a trusting, non-judgmental relationship encourages open communication and supports long-term adherence.